Business
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that initial clinical results and preclinical data for zovegalisib (RLY-2608) in vascular anomalies will be presented at the International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2026, taking place May 1
About this update from Relay Therapeutics, Inc.
[{"type":"image","alt":"Relay Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Relay Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":131,"url":"https://media.zenfs.com/en/globenewswire.com/9a37786351f2b419db7f6dccc70bf15f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Vu9j.OPRikxfmERBKVL9VQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4Mw--/https://media.zenfs.com/en/globenewswire.com/9a37786351f2b419db7f6dccc70bf15f","width":300,"height":131}},"lazy":false},{"type":"text","content":"CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that initial clinical results and preclinical data for zovegalisib (RLY-2608) in vascular anomalies will be presented at the International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2026, taking place May 19-22, 2026, in Philadelphia. The company anticipates reporting clinical data on approximately 20 efficacy-evaluable patients.","length":625,"tagName":"p"},{"type":"text","content":"Late Breaking Clinical Abstract:Abstract Title: Initial Results of Zovegalisib (RLY-2608), a Mutant-selective PI3Kα Inhibitor in Adult and Pediatric Patients with PIK3CA-Driven Vascular Malformations Abstract Number: 488Session: Late Breaking Abstract SessionDate/Time: Wednesday, May 20, 4:30 p.m. ET","length":305,"tagName":"p"},{"type":"text","content":"Preclinical Abstract:Abstract Title: Zovegalisib (RLY-2608), a Novel, Mutant-selective, PI3Kα Inhibitor, Induces Lesion Regression, with Minimal Hyperinsulinemia, in Murine Models of PIK3CA-mutant Vascular Malformations Abstract Number: 404Session: Session 9 - CombinedDate/Time: Friday, May 22, 11:10 a.m. ET","length":313,"tagName":"p"},{"type":"text","content":"The presentations will be available at the start of the sessions on the company’s website at https://relaytx.com/publications/.","length":132,"tagName":"p"},{"type":"text","content":"About ZovegalisibZovegalisib is the lead program in Relay Therapeutics’ efforts to discover and develop mutant-selective inhibitors of PI3Kα, the most frequently mutated kinase in all cancers and all vascular anomalies. Zovegalisib has the potenti...